anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the field of daily chemicals. An explosive salt comprises an explosive salt body, wherein the inside of the explosive salt body is provided with a containing cavity capable of containing a content. Before the explosive salt is used, the specific shape of the built-in object cannot be known; when in use, the built-in substances are gradually exposed along with the dissolution of the explosive salt; after use, the built-in object is completely separated from water. The use process is surprise, after the explosive salt is dissolved and the original shape is lost, the color, the fragrance and the taste are lost, the strong interestingness is still maintained, and the use pleasure is greatly improved. The preparation method of the explosive salt is simple and efficient, the energy consumption is low, and the yield of finished products reaches more than 98%. The product is prepared by compression molding to obtain semi-finished products, and then the semi-finished products are put into a built-in object for compression molding to obtain finished products. The method has the advantages that the influence of stress of the built-in objects is small in the process of molding the finished product, the explosion salt cannot cause body spalling due to the fact that the material of the built-in objects is too soft or the shape is special, and the method improves the production yield and simultaneously increases the richness of selectable materials and shapes of the built-in objects.
In order to provide pain patients with an individualized approach to their pain problem after MIRP we developed an electronic medical record coupled to a set of telemetric medical-grade devices. Appi@Home (Antwerp Personalized Pain Initiative) supports an innovative approach to (sub)acute conditions by offering a platform for continuous follow-up. Patients are provided with a toolbox and an app that continuously collects objective outcome data (i.e. pain intensity, sleep quality, physical activity). The integrated system allows the care givers to respond very quickly to changing clinical conditions of the patient, making a very adaptive and individualized follow-up possible for these patients. In addition, the patient becomes an active participant in the global therapeutic approach.

Patients receive the toolbox two week prior to surgery with access to the internet platform for questionnaires fill-in procedure. Up to ten week after surgery pain intensity, sleep quality and physical activity will be monitored subjectively by a scoring table (0-10, 0 no pain-bad sleeping quality-no activity, 10 maximum of pain-excellent sleeping quality- a lot of activity) and objectively by blood pressure device, oxygen saturation monitoring, activity tracker and sleep registration tool.
This study is a clinical observational cohort study. All chronic hepatitis B patients were diagnosed and treated in the liver disease department of the Hepatology Center of Beijing Ditan Hospital affiliated to Capital Medical University and those who received antiviral therapy (interferon and nucleoside analogues) reached HBsAg\<100 IU/ml. The enrolled subjects were divided into the following six observation cohorts: 1) chronic Hepatitis B patients in the immunological control period, without any clinical treatment intervention in this cohort; 2) After interferon therapy, HBsAg\<100 IU/ml, continued interferon therapy in this cohort; 3) After interferon therapy, HBsAg\<100 IU/ml, stopped interferon treatment in this cohort; 4) After interferon therapy, HBsAg\<100 IU/ml, sequential nucleoside analog treatment in this cohort; 5) After nucleoside analogue treatment, HBsAg\<100 IU/ml, sequential interferon treatment in this cohort; 6) After treated with nucleoside analogues, HBsAg\<100 IU/ml, continuing the nucleoside analog treatment in this cohort. The follow-up observation period was 96 weeks under non-planned intervention. During the observation period, HBV DNA loads, HBsAg/anti-HBs, HBeAg/anti-HBe and biochemical indicators, serum AFP and liver imaging (liver ultrasound) were examined regularly. The main evaluation index was the incidence of HBsAg disappearance during the observation period. Secondary evaluation indicators: the rate of HBV DNA turning positive, the rate of HBeAg turning positive and hepatitis incidence. To observe the inactive carrier status of low HBsAg content and the incidence of HBsAg disappearance, clinical outcomes and influencing factors in patients with CHB under different antiviral interventions.
The study group will include 28 patients with indications (impacted third molars that exerts pressure on the adjacent tooth and cause inflammation process in the surrounding tissue; absence of antagonist; pericorinitis; periodontitis; periodontal pockets) for the impacted third molar extraction. Patients will be comparable by gender and age, the patients age will be between 18 and 70 years. Patients should be with therapeutic and surgical oral hygiene and without co-morbidities.
There is an urgent need for new high-quality markers for the early detection of hepatocellular carcinoma (HCC). Åström et al. suggested that S2-bound α1-acid glycoprotein (AGP) might be a promising marker. Consequently, we evaluated the predictive advantage of S2-bound AGP in the early detection of HCC. In a retrospective case-control study of patients chronically infected with hepatitis C virus (HCV) and treated with direct-acting antiviral agents (n = 93), we measured S2-bound AGP using the HepaCheC® ELISA kit (Glycobond AB, Linköping, SE) at the start of treatment, end of treatment and follow-up (maximum: 78 months). Patients were retrospectively propensity score matched (1:2). Thirty-one patients chronically infected with HCV developed HCC after a sustained virological response, while 62 did not. In addition, samples of patients with chronic hepatitis B virus infection, metabolic dysfunction-associated steatotic liver disease and HCC of different etiologies were analysed. S2-bound AGP elevation in HCC patients was confirmed. However, we did not observe a predictive advantage of S2-bound AGP for the early detection of HCC during treatment and follow-up. Interestingly, S2-bound AGP levels correlated with aspartate aminotransferase (ρ = .56, p = 9.5×10-15) and liver elastography (ρ = .67, p = 2.2×10-16). Of note, S2-bound AGP decreased in patients chronically infected with HCV after treatment-induced HCV clearance. Fucosylated S2-bound AGP levels were elevated in patients with chronic HCV and HCC. The potential role of S2-bound AGP as a novel tumour marker requires further investigation.
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephropathy. There is evidence that mesangial C3 deposition plays a role in the development of the disease. The aim of this study was to examine the effect of C3 deposition on the prognosis of IgAN patients.
METHOD: The study included 1135 patients with biopsy-confirmed IgAN from the database of the Turkish Nephrology Association Glomerular Diseases Working Group (TSN-GOLD). Patients were excluded from the study if they were aged < 18 or > 75 years or if C3 staining had not been performed in the immunofluorescent analysis. C3 deposition was defined as an immunofluorescence intensity of C3 ≥ 2 + within the mesangium. The primary endpoints were the development of end-stage renal disease, a 30% decrease in glomerular filtration rate compared to the basal value or an elevation in proteinuria to a nephrotic level (3.5 gr/day).
RESULTS: Mesangial C3 deposition was observed in 603 (53.1%) patients. No statistically significant difference was found at baseline between the groups with and without mesangial C3 deposition, as for age, sex, BMI, proteinuria level, or the presence of hypertension. In the follow-up period with a mean duration of 78 months, no significant difference was found between the two groups regarding the primary endpoints (p = 0.43). A significant correlation between C3 deposition and segmental glomerulosclerosis (S1) according to the Oxford MEST-C classification was found (p = 0.001).
CONCLUSION: Although a correlation was observed between mesangial C3 deposition and the S1 MEST-C classification, mesangial C3 deposition was not a prognostic factor in IgAN.
A composition comprises valerian, impatiens spp., and wild clematis, their oils, extracts, derivatives or synthetic equivalents thereof. Preferably the composition also comprises a C2-C8 alcohol such as ethanol or a phenyl ethyl alcohol and may further include a lipophilic organic diluent such as propylene glycol. The composition preferably comprises valerian in an amount from about 0.0625% to about 0.250% w/v, impatiens spp. in an amount from about 0.15% to about 0.6% w/v, wild clematis in an amount from about 0.15% to about 0.6% w/v, a C2-C8 alcohol or phenyl ethyl alcohol in an amount from about 0.5% to about 97% w/v and a lipophilic organic diluent in an amount from about 2.5% to about 99% based on the total volume of the composition. Preferably the composition is useful in the treatment or prevention of stress, or for inducing a friendly behaviour in a non-human subject, in particular cats and dogs, where the composition may be administered by a spray or diffuser. A composition consisting of valerian, impatiens spp., wild clematis their oils, extracts or derivatives thereof, ethanol and propylene glycol is also provided.
Greater than 30 million people have diabetes. Over time diabetic patients need more and more medications and develop numerous medical complications. Remission of Type 2 Diabetes (T2DM) would have profound effects on people with diabetes with respect to overall health improvement (insulin sensitivity(Si), cardiovascular risk factors(CVR), inflammation markers (IC)), reduction of retinopathy, nephropathy, neuropathy and reduction in medical costs. Methods to accomplish this have not yet been determined, however, it is generally accepted that non-drug methods to treat T2DM is the most cost effective and have the fewest side effects. The primary risk factor for T2DM is obesity. Our randomized clinical trials comparing the effects of High Protein (HP) vs High Carbohydrate (HC) weight loss diets in obese, prediabetic(IGT) women and men where all foods were provided daily for 6 months(mo) showed that while both diet groups had similar weight loss, 100% of HP diet subjects had remission from IGT to Normal Glucose Tolerance(NGT), but only 33% of HC diet group had remission. Also, the HP diet provided greater improvement in Si, CVR, IC, and an increase in % lean body mass (LBM) compared to the HC diet demonstrating that weight loss is not the only factor involved in remission. Based on these findings, we now propose to investigate effects of HP and HC weight loss diets in Newly Diagnosed T2DM (NT2DM) women and men for 6 mo. Our long term goal is to establish a weight loss diet plan for remission of NT2DM which would be adaptable for use in physicians' clinics and metabolomics predictors for assess-ment of remission. The overall objective of this study is to determine if remission of NT2DM can be induced by dietary manipulation using a HP diet and the pathobiology of this remission. We hypothesize that NT2DM subjects will have remission to NGT on the HP diet when they are provided the food and daily menus for compliance. The rationale is the HP diet is palatable for subjects to continue after the 6 mo study and stay in remission using diet plans we provide. We will compare the effects of the HP vs HC diet on remission. Specific aims of this study are to determine the effects of the HP and HC diets on NT2DM obese subjects in a 6 mo feeding study and determine: (a)remission of NT2DM to NGT, (b)weight loss and LBM preservation, (c)improvements in metabolic markers, CVRs, IC, epigenetic DNA methylation changes and pathways involved with remission and metabolomic markers to establish predictive markers of remission of NT2DM. This study is innovative in that we propose to use a non-pharmaceutical means (HP diet) for remission of T2DM diabetes and weight loss and determine the pathobiology involved in improvement in metabolic and CVRs by interrogating the samples with emerging technologies. The proposed research is significant because if we can demonstrate the HP diet cause remission of NT2DM to NGT along with other metabolic improvements, it would be a significant improvement in health risk and medical cost to subjects
When patients come to the outpatient clinic for a check-up 15 days after discharge, they will be asked to fill out the Personal Information Form, Self-Efficacy Scale, Self-Care Ability Scale, and Quality of Life Scale by face-to-face information collection method.Patients will receive routine treatment, care and checks in line with the institutional policy. A web designed training program will not be implemented. One month after the pre-test data is collected, patients will be called and asked to fill out the self-efficacy scale, self-care ability scale and quality of life scale when they come to the outpatient clinic.
The chief aim of this protocol is to determine the efficacy of negative work progressive resistance exercise (PRE) in the management of sarcopenia in older male Veterans at the DC VAMC. This proposed study is a randomized clinical trial using a single-arm, delayed cross-over design with repeated measures. This method is a patient-first approach to clinical research that permits all participants to receive the intervention while allowing the investigators to conduct both within subjects and between subjects comparisons with a modest study enrollment. During the "pre-treatment period" we will recruit, screen, and consent 30 older men with sarcopenia. The participants will be randomized into two groups: active treatment and delayed treatment. The initial "active treatment" and "delayed treatment" periods will last 12 weeks. After 12 weeks, the participants in the delayed treatment group will crossover (without a washout period) and start 12 weeks of intervention. All participants will detrain and be monitored for follow up during their respective 12-week "post treatment" period. Outcome measures include post-exercise changes in metabolic and inflammatory markers, muscle morphology, strength, and functional status.
<P>PROBLEM TO BE SOLVED: To provide a method for quantitation of sample properties using contrast enhancement from saturation transfer.  <P>SOLUTION: The manipulation of RF irradiation to a subject in which a CEST agent has been administered is employed to determine a biological parameter in vivo in conjunction with an MRI imaging process. The exchange rate of the CEST agent is determined through RF manipulation which in turn enables the determination of a biological parameter through standard calibration techniques. The exchange rate of CEST agents is modulated as a function of many biological parameters, such as pH. MRI apparatuses and computer program products configured for determining exchanges rates of CEST agents in vivo are also disclosed.  <P>COPYRIGHT: (C)2007,JPO&INPIT
It has been established that inhibition of the expression and function of nicotinamide phosphoribosyltransferase (NAMPT) can treat Pulmonary Arterial Hypertension (PAH) in a patient in need thereof. Compositions and methods of an effective amount of one or more inhibitors of intracellular NAMPT (iNAMPT), extracellular NAMPT (eNAMPT), or a receptor of eNAMPT, to treat PAH are provided. The compositions and methods reduce, or reverse the physiological vascular changes associated with the onset and progression of PAH. Inhibitors of NAMPT or receptors of NAMPT include small molecules, antibodies and antigen binding fragments thereof. Dosage forms including monoclonal antibody inhibitors of NAMPT or NAMPT receptors in an amount between 10 mg and 400 mg are provided. Dosage forms including small molecule inhibitors of NAMPT in an amount between 10 mg/kg and 3.5 mg/kg body weight of the recipient are also provided.
The control arm offered to subjects with dystonia and other involuntary muscle disorders, participants will be followed at baseline and 6 months similar to what will be done in active exercise arm but this arm will not receive exercise. They will be monitored with an activity monitor.
Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
PURPOSE: A composition containing a Rhodomyrtus tomentosa extract for preventing and treating inflammatory diseases is provided to be used in a medical industry for treating inflammatory diseases and a cosmetic industry related to the control of skin inflammation. CONSTITUTION: An anti-inflammatory composition contains a Rhodomyrtus tomentosa extract as an active ingredient. The extract is prepared from Eupatorium japonicum Thunb. ex Murray flowers using water, C1-C5 alcohol, and a mixture thereof. A pharmaceutical composition for preventing and treating inflammatory diseases contains the extract as an active ingredient. The inflammatory diseases are selected among dermatitis, allergy, gastric ulcer, duodenal ulcer, hepatitis, esophagitis, gastritis, colitis, pancreatitis, nephritis, stomach cancer, generalized edema, and local edema. A cosmetic composition for preventing and treating inflammatory diseases contains the extract as an active ingredient.
UNLABELLED: The combination of endocrine therapy and CDK4/6 inhibitors such as palbociclib is an effective and well-tolerated treatment for estrogen receptor-positive (ER+) breast cancer, yet many patients relapse with therapy-resistant disease. Determining the mechanisms underlying endocrine therapy resistance is limited by the lack of ability to fully recapitulate inter- and intratumor heterogeneity in vitro and of availability of tumor samples from women with disease progression or relapse. In this study, multiple cell line models of resistant disease were used for both two-dimensional (2D)- and three-dimensional (3D)-based inhibitor screening. The screens confirmed the previously reported role of pro-proliferative pathways, such as PI3K-AKT-mTOR, in endocrine therapy resistance and additionally identified the transcription-associated cyclin-dependent kinase CDK9 as a common hit in ER+ cell lines and patient-derived organoids modeling endocrine therapy-resistant disease in both the palbociclib-sensitive and palbociclib-resistant settings. The CDK9 inhibitor, AZD4573, currently in clinical trials for hematologic malignancies, acted synergistically with palbociclib in these ER+in vitro 2D and 3D models. In addition, in two independent endocrine- and palbociclib-resistance patient-derived xenografts, treatment with AZD4573 in combination with palbociclib and fulvestrant resulted in tumor regression. Tumor transcriptional profiling identified a set of transcriptional and cell-cycle regulators differentially downregulated only in combination-treated tumors. Together, these findings identify a clinically tractable combination strategy for overcoming resistance to endocrine therapy and CDK4/6 inhibitors in breast cancer and provide insight into the potential mechanism of drug efficacy in targeting treatment-resistant disease.
SIGNIFICANCE: Targeting transcription-associated CDK9 synergizes with CDK4/6 inhibitor to drive tumor regression in multiple models of endocrine- and palbociclib-resistant ER+ breast cancer, which could address the challenge of overcoming resistance in patients.
Sacroiliac screws (SISs) have been used since Vidal et al introduced them in 1973. Since that, SIS fixation has become a common technology in fixing pelvic posterior ring injuries with important progress in the past 20 years. Currently, SIS fixation represents the only minimally invasive technique to stabilize the posterior pelvic ring. For that reason, it is steadily gaining popularity, becoming one of the most commonly used techniques. The sacrum, serving as the foundation of the spine, transmits the stress between spine and pelvis through sacroiliac joints. Thus, the goal of surgical fixation is the reconstruction of the spino-pelvic-junction to allow early weight-bearing and to facilitate nursing care, particularly for multiple injured patients.

As a result of the deforming forces acting perpendicular to the implant axis, routine ilio-sacral screws fixation may not provide adequate stabilization, especially in certain unstable injuries. Longer trans-sacral screws that traverse the entire upper sacrum and exit the contralateral iliac cortex may improve holding power and also stabilize concomitant contralateral posterior pelvic injuries. These trans-sacral screws are reliably safe to insert using routine intraoperative fluoroscopy, and they provide durable fixation.
FIELD: medicine, biochemistry, hormones, peptides. SUBSTANCE: invention relates to peptide of the formula:   where A 1  means Ser; A 3  means Ser or Aib; A 5  means Ile; A 7  means Leu or Cha; A 8  means Met or Nle; A 11  means Leu or Cha; A 12  means Gly or Aib; A 15  means Leu or Cha; A 16  means Asn or Aib; A 17  means Ser or Aib; A 18  means Met, Nle or Acc; A 19  means Glu or Aib; A 21  means Val; A 22  means Acc, Glu or Cha; A 23  means Trp, Acc, Cha or Leu; A 24  means Leu, Acc or Cha; A 27  means Lys, Leu, hArg, Ac or Cha; A 28  means Leu, Acc or Cha; A 29  means Glu, Gln or Aib; A 30  means Asp, Lys, Nle or Acc; A 31  means Val, Leu, Nle, Acc or Cha; A 32  means His; A 33  means Asn; A 34  means Phe, Tyr or Aib; each of radicals R 1  and R 2  means H independently each of other; and R 3  means NH 2  under condition that at least one of amino acid   means Acc. Invention relates also to its pharmaceutically acceptable salt and these peptides are analogs of parathyroid gland hormone. Compounds show high binding degree with parathyroid hormone receptors and stimulate activity of adenylate cyclase. EFFECT: valuable medicinal and biochemical properties of peptides. 15 cl, 4 tbl
The dust mites D. farinae and D. pteronyssinus are the major source of allergens in house dust. 14 The efficacy of immunotherapy for Type I hypersensitivity (i.e. allergy) to airborne allergens 2,15,16 including dust mite has been well established. Specifically, immunotherapy for allergic hypersensitivity to house dust mite allergens has been addressed in a 1995 Cochrane meta-analysis of 20 randomized, controlled trials of immunotherapy, 17 and two subsequent updated Cochrane meta-analysis published in 1999 18 and 2003 19. In addition, efficacy for immunotherapy in rush or cluster protocols, in which the dose escalation is compressed over days or weeks, has also been demonstrated. 20,21